Specialty Pharmacy

Epidermal growth factor receptors may offer cancer treatment target.

A look back at recent developments in cancer research.

A regular dose of aspirin may reduce the risk of early cancer development.

An HCV infection may cause more than just liver damage.

Children vaccinated before starting HIV therapy found to be at risk.

Top stories of the week on Specialty Pharmacy Times from August 17 to 21.

Out-of-pocket costs projected to drop from 11.6% in 2013 to 10% in 2024.

Treatment uses photodynamic therapy with compounds that make cancer cells vulnerable to reactive oxygen species.

Researchers seek to improve treatment for autoimmune diseases, including rheumatoid arthritis, gout, Crohn's disease, and lupus.

The FDA is considering expanding the use of Merck's pembrolizumab as a first-line treatment for advanced melanoma.

More companies are requiring prior authorization before specialty drugs are purchased under employer health plan.

Medicare Part D contracting transparencies among issues that prompted action.

Rheumatoid arthritis treatment remains consistently well tolerated over long-term evaluation.

Nephropathic cystinosis drug Procysbi now available in delayed-release capsules for young children.

Changes still needed to further improve the decision-making process for patients.

Depression and fatigue loom as issues to overcome for patients with multiple sclerosis.

Women and individuals who suffered childhood sexual abuse among most vulnerable IBD patients.

Specialty pharmacies need to carefully evaluate multiple aspects of manufacturer-sponsored free product programs.

Study finds coffee consumption improves survival odds in some patients.

Research may lead to a gel that instantly destroys viral particles.

In the long wake of a deadly meningitis outbreak from tainted drugs distributed by a compounding pharmacy in Massachusetts, state regulators have been increasing their inspections of pharmacies with complaints.

Patients with any type of health insurance receive preventive care for chronic diseases at rates up to 3 times higher than their uninsured counterparts, the US Centers for Disease Control and Prevention has found.

Debate continues around eligibility requirements for pricey new high cholesterol drug class.

Novel kinase cascade found to regulate cancer growth.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses URAC specialty practice standards.

Sprycel label now includes 5-year first-line efficacy and safety data in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

Low bleeding rates found with intervals of up to 2 weeks between infusions.

Company alleged to have marketed products as viable treatments for cancer, malaria, herpes, and heart disease.